Aromatase Inhibitor and Durvalumab in Postmenopausal Breast Cancer

NCT03874325 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

17

Enrollment

OTHER

Sponsor class

Stopped lost funding

Conditions

Breast Cancer
Hormone Receptor Positive Tumor

Interventions

DRUG: Durvalumab
DRUG: Anastrozole 1mg
DRUG: Letrozole 2.5mg
DRUG: Exemestane 25 MG

Sponsor

H. Lee Moffitt Cancer Center and Research Institute

Collaborators

[object Object]